Robert S. Landsman

Array ( [id] => 10506167 [patent_doc_number] => 09234032 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-01-12 [patent_title] => 'Fed-batch methods for producing adalimumab' [patent_app_type] => utility [patent_app_number] => 14/157460 [patent_app_country] => US [patent_app_date] => 2014-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 47212 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14157460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10459943 [patent_doc_number] => 20150344958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-03 [patent_title] => 'A SCREENING METHOD, A KIT, A METHOD OF TREATMENT AND A COMPOUND FOR USE IN A METHOD OF TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/759747 [patent_app_country] => US [patent_app_date] => 2014-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 14984 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14759747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9596786 [patent_doc_number] => 20140193467 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-10 [patent_title] => 'COMPOSITIONS COMPRISING TNF-SPECIFIC ANTIBODIES FOR ORAL DELIVERY' [patent_app_type] => utility [patent_app_number] => 14/152046 [patent_app_country] => US [patent_app_date] => 2014-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18605 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14152046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9602651 [patent_doc_number] => 20140199333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-17 [patent_title] => 'Aquaporin-4 Peptides, Compositions and Methods of Use' [patent_app_type] => utility [patent_app_number] => 14/102294 [patent_app_country] => US [patent_app_date] => 2013-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 17759 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14102294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9596737 [patent_doc_number] => 20140193418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-10 [patent_title] => 'ANTI-HUMAN EPO RECEPTOR ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/097972 [patent_app_country] => US [patent_app_date] => 2013-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17179 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14097972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10020646 [patent_doc_number] => 09063124 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-23 [patent_title] => 'Method for identifying compounds that modulate a T2R taste receptor' [patent_app_type] => utility [patent_app_number] => 14/085403 [patent_app_country] => US [patent_app_date] => 2013-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 81 [patent_figures_cnt] => 8 [patent_no_of_words] => 42521 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14085403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10116051 [patent_doc_number] => 09150923 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-10-06 [patent_title] => 'Methods of identifying FHL1 mutations associated with novel X-linked muscular myopathies' [patent_app_type] => utility [patent_app_number] => 14/077887 [patent_app_country] => US [patent_app_date] => 2013-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 10 [patent_no_of_words] => 10745 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14077887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10082503 [patent_doc_number] => 09119833 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-01 [patent_title] => 'Administration of relaxin to treat nephrogenic diseases of water imbalance involving aquaporin-4' [patent_app_type] => utility [patent_app_number] => 14/074759 [patent_app_country] => US [patent_app_date] => 2013-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 17636 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14074759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9608435 [patent_doc_number] => 08785602 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-07-22 [patent_title] => 'EMP2 antibodies and methods of use thereof for causing regression of a solid tumor or symptoms thereof' [patent_app_type] => utility [patent_app_number] => 14/064956 [patent_app_country] => US [patent_app_date] => 2013-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 38481 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14064956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9510955 [patent_doc_number] => 20140147446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-29 [patent_title] => 'ANTIBODY THERAPY FOR MODULATING FUNCTION OF INTESTINAL RECEPTORS AND METHODS OF TREATING DIABETES AND OBESITY' [patent_app_type] => utility [patent_app_number] => 14/061301 [patent_app_country] => US [patent_app_date] => 2013-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11454 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14061301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10063914 [patent_doc_number] => 09102747 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-08-11 [patent_title] => 'cDNA-derived nucleic acids encoding red-shifted channelrhodopsins' [patent_app_type] => utility [patent_app_number] => 14/053129 [patent_app_country] => US [patent_app_date] => 2013-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 32832 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14053129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10110054 [patent_doc_number] => 09145458 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-29 [patent_title] => 'Antibodies specific for TGF-β and methods of treatment thereof' [patent_app_type] => utility [patent_app_number] => 14/038436 [patent_app_country] => US [patent_app_date] => 2013-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 56635 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14038436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10324406 [patent_doc_number] => 20150209410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF DISEASES' [patent_app_type] => utility [patent_app_number] => 14/426197 [patent_app_country] => US [patent_app_date] => 2013-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 9272 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14426197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10090253 [patent_doc_number] => 09127068 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-08 [patent_title] => 'Nucleic acids encoding human glucagon receptor antibodies' [patent_app_type] => utility [patent_app_number] => 14/014517 [patent_app_country] => US [patent_app_date] => 2013-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 28713 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14014517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9339629 [patent_doc_number] => 20140066411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-06 [patent_title] => 'PHARMACEUTICAL COMPOSITIONS FOR EXTENDED RELEASE OF AZO-BONDED 5-AMINOSALICYLIC ACID COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 14/012484 [patent_app_country] => US [patent_app_date] => 2013-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 16040 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14012484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10367111 [patent_doc_number] => 20150252116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-10 [patent_title] => 'ANTI-PROLACTIN RECEPTOR ANTIBODY FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 14/421609 [patent_app_country] => US [patent_app_date] => 2013-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7775 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14421609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330569 [patent_doc_number] => 20140057351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'IDEOTYPICALLY MODULATED PHARMACOEFFECTORS FOR SELECTIVE CELL TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/010186 [patent_app_country] => US [patent_app_date] => 2013-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10948 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14010186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9262149 [patent_doc_number] => 20130344078 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-26 [patent_title] => 'EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES' [patent_app_type] => utility [patent_app_number] => 13/972670 [patent_app_country] => US [patent_app_date] => 2013-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 38460 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13972670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10348940 [patent_doc_number] => 20150233944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'DIAGNOSIS AND TREATMENT OF MOTILITY DISORDERS OF THE GUT AND BLADDER, AND OF FIBROMYALGIA' [patent_app_type] => utility [patent_app_number] => 14/428195 [patent_app_country] => US [patent_app_date] => 2013-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 15425 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14428195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356657 [patent_doc_number] => 20220017453 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2022-01-20 [patent_title] => IGM COMPOSITIONS AND METHODS OF MUCOSAL DELIVERY OF THESE COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/052671 [patent_app_country] => US [patent_app_date] => 2019-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052671 [rel_patent_id] =>[rel_patent_doc_number] =>)